BPC-157 & TB-500 40mg

£115.00

Category: Alluvi Retatrutide Tags: alluvi, alluvi bpc 157, alluvi bpc 157 tb500, alluvi bpc-157 & tb-500 40mg, alluvi bz, alluvi bz reviews, alluvi healthcare, alluvi healthcare bpc 157, alluvi healthcare retatrutide, alluvi healthcare retatrutide pens, alluvi healthcare uk, alluvi reta, alluvi reta pen, alluvi reta pen review, alluvi retatrutide, alluvi retatrutide reviews, alluvi retatrutide uk, alluvi reviews, alluvi shop, alluvi uk, bpc 157 and tb 500, bpc 157 and tb 500 dosage, bpc 157 dosage, bpc 157 uk, bpc-157 & tb-500 40mg, how often to inject bpc 157 and tb 500, how to take bpc 157 and tb 500, how to take tb 500 and bpc 157, is alluvi healthcare legit, reta pen, reta pen 40mg, reta pen uk, reta pens, reta peptide, reta peptides, reta uk, reta weight loss, reta weight loss drug, retatrutide alluvi, retatrutide cost, retatrutide how to get, retatrutide pen, retatrutide peptide, retatrutide uk, retatrutide weight loss, tb 500 and bpc 157, what is tb 500 and bpc 157, where to buy bpc 157 and tb 500

Description
Reviews (0)

Alluvi Reta Pen | BPC-157 & TB-500

Alluvi Reta Pen, BPC-157 & TB-500. Alluvi Retatrutide, BPC-157, and TB-500 (40 mg) are research-grade substances that are only provided for use in laboratories and research and development; they are not intended for use by humans or animals. While BPC-157 and TB-500 are peptides frequently examined for tissue repair and recovery, retatrutide is a GLP-1 multi-agonist studied for weight loss. BPC-157 & TB-500 40mg

Type: GLP-1/GIP/GCGR multi-agonist peptide.
Research Goals: Examined for weight loss, appetite management, and metabolic control.
Results: Using high-dose regimens, clinical studies have demonstrated an average weight loss of 18.3 kg over 48 weeks, with some patients experiencing a reduction of up to 22.5%.
Mechanism: Reduces calorie intake without enforced dieting by improving satiety signals.
Formulation: Provided in pre-filled 20 mg or 40 mg pens for controlled laboratory investigation of delivery systems and compound stability.
Important Note: Only for research and development; not authorized for therapeutic use.

Alluvi Reta Pen | TB-500 and BPC-157 (40 mg Combination)

Type: Blend of peptides (20 mg BPC-157 + 20 mg TB-500).
Research Goals: Examined for skin elasticity, bone strength, tendon healing, and joint support.
Formulation: Provided in a 40 mg pre-filled pen kit that is sealed for assessment of the injection method and compound stability.
Storage: Do not freeze; refrigerate between 2 and 8°C.
Administration (R&D context): For controlled trials, pens enable dosage adjustments in increments of 2.5 mg or 5 mg.
Important Note: This formulation is not intended for human or veterinary use, just like retatrutide.

Alluvi Reta Pen | Comparison Table

Compound	Type/Category	Primary Research Focus	Dosage Form	Key Findings
Retatrutide	GLP-1 multi-agonist	Weight loss, metabolic control	20mg / 40mg pens	Up to 22.5% weight reduction in trials
BPC-157	Peptide	Tissue repair, gut healing	20mg (part of combo)	Studied for tendon/ligament recovery
TB-500	Peptide	Muscle & tissue recovery	20mg (part of combo)	Investigated for wound healing, repair

Risks and Restrictions

Unapproved for medical use: These substances are solely provided for research and development and shouldn’t be applied to people or animals.
Potential abuse: Off-label use may be tempted by online availability; however, there are unknown safety hazards involved.
Regulatory status: BPC-157 and TB-500 are not FDA-approved medications, while retatrutide is still under research.

Important Takeaway
Alluvi’s advanced peptide formulations, BPC-157/TB-500 40 mg and Retatrutide 40 mg, are intended for controlled laboratory studies on tissue repair and weight control. Although preliminary research indicates encouraging outcomes in terms of weight loss and recuperation, it is still purely experimental and not meant for human consumption. BPC-157 & TB-500 40mg